bosentan anhydrous has been researched along with Melanoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S; Li, XY; Li, YH; Lin, QQ; Liu, KL; Meng, FH; Qian, XH; Wang, DP; Xue, WH | 1 |
| Andrews, MC; Arozarena, I; Brunton, H; Cooper, ZA; Dummer, R; Ferguson, J; Flaherty, KT; Frederick, DT; Haass, NK; Kmarashev, J; Levesque, MP; McEntegart, S; Miskolczi, Z; Rodriguez, J; Rowling, EJ; Sloss, O; Smith, MP; Spoerri, L; von Kriegsheim, A; Wargo, JA; Wellbrock, C | 1 |
| Kaneko, T; Saji, T; Sato, K; Sugi, K; Takahashi, K | 1 |
| Ballmer, A; Brady, B; Clingan, PR; Hersey, P; Kefford, RF; Morganti, A | 1 |
| Berger, Y; Bernasconi, CC; Juillerat-Jeanneret, L | 1 |
| Ballmer, A; Beith, JM; Clozel, M; Kefford, R; Kusic, R; Millward, M; Morganti, A; Nayler, O; Segal, E; Shreeniwas, R; Trotter, JM; Van Hazel, GA; Wyld, DK | 1 |
2 trial(s) available for bosentan anhydrous and Melanoma
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bosentan; Dacarbazine; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Sulfonamides | 2010 |
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Australia; Bosentan; Endothelin Receptor Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Receptors, Endothelin; RNA, Messenger; Skin Neoplasms; Sulfonamides; Tablets; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
4 other study(ies) available for bosentan anhydrous and Melanoma
| Article | Year |
|---|---|
Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Design; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Oxidoreductases Acting on CH-NH Group Donors; Protein Binding; Pyrimidines; Rats, Sprague-Dawley; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.
Topics: Animals; Antineoplastic Agents; Bosentan; Cell Line, Tumor; Disease Models, Animal; Endothelin Receptor Antagonists; Heterografts; Humans; Melanoma; Mice, Nude; Neoplasm Transplantation; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Zebrafish | 2017 |
Unexpected pulmonary hypertensive crisis after surgery for ocular malignant melanoma.
Topics: Blood Pressure; Bosentan; Choroid Neoplasms; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Pulmonary Artery; Sulfonamides; Tomography, X-Ray Computed | 2014 |
Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.
Topics: Alkylating Agents; Antineoplastic Agents; Apoptosis; Bosentan; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Drug Synergism; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fas Ligand Protein; Genetic Variation; Humans; Melanoma; Membrane Glycoproteins; Oligopeptides; Peptides, Cyclic; Piperidines; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Tumor Necrosis Factors | 2006 |